The Emerging Jamboree of Transformative Therapies for Autoimmune Diseases

Abstract

Standard treatments for autoimmune and autoinflammatory disorders rely mainly on immunosuppression. These are predominantly symptomatic remedies that do not affect the root cause of the disease and are associated with multiple side effects. Immunotherapies are being developed during the last decades as more specific and safer alternatives to small molecules with broad immunosuppressive activity, but they still do not distinguish between disease-causing and protective cell targets and thus, they still have considerable risks of increasing susceptibility to infections and/or malignancy. Antigen-specific approaches inducing immune tolerance represent an emerging trend carrying the potential to be curative without inducing broad immunosuppression. These therapies are based on antigenic epitopes derived from the same proteins that are targeted by the autoreactive T and B cells, and which are administered to patients together with precise instructions to induce regulatory responses capable to restore homeostasis. They are not personalized medicines, and they do not need to be. They are precision therapies exquisitely targeting the disease-causing cells that drive pathology in defined patient populations. Immune tolerance approaches are truly transformative options for people suffering from autoimmune diseases.

Nanomaterials-Mediated Immunomodulation for Cancer Therapeutics

“…This fine-tuning of the immune system can either occur naturally, as a part of homeostatic regulation or it can be induced by medical interventions to achieve a therapeutic effect. Immunosuppressive therapies are usually applied in the case of auto-immune diseases ( Carballido et al, 2020 ) and immuno-stimulation is a course of action for cancer and infectious diseases ( Dittmer and Olbrich, 2003 ; García-Martínez et al, 2018 ). The recent trend is to apply nanotechnology to design alternative treatment approaches which can induce therapeutic effects at the target site while causing minimum collateral damage and adverse effects ( Li, T. et al, 2020 ; Tan et al, 2020 ).…”

A century later, still fighting back: antigen‐specific immunotherapies for type 1 diabetes

“…Indeed, antigen‐specific immunotherapy has proven feasible and safe, although moderately optimistic in terms of tolerance re‐establishment. However, several antigen‐specific strategies using different carrier methods—thoroughly reviewed elsewhere 58 —are rapidly working their way up from preclinical research (Figure 1).…”

Best Achievements in Clinical Thyroidology in 2020

“…The conventional treatment modalities for Graves’ disease have remained unchanged for the past 70 years [ 7 ]. Recently, novel therapeutic agents targeting the CD40-CD154 co-stimulatory pathway or the insulin-like growth factor I receptor (IGF-IR) were developed [ 8 ]. Kahaly et al [ 9 ] conducted an open-level phase II proof-of-concept study of iscalimab, an anti-CD40 monoclonal blocking antibody in 15 Graves’ disease patients.…”